Financial Personal
Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair
– Breakthrough Therapy designation for NTX-001 granted by FDA – Preparation is underway for the Phase 3 program to begin in early 2025 CHESTERBROOK, Pa. — Neuraptive Therapeutics, Inc. today announced that NTX-001 has been granted Breakthrough
CHESTERBROOK, Pa. -- Neuraptive Therapeutics, Inc. today announced that NTX-001 has been granted Breakthrough Therapy Designation, thus providing the potential for accelerated development for patients with peripheral nerve injury requiring repair. This designation follows the results from the Phase 2 NEUROFUSE study and several interactions with the FDA. NTX-001 has the potential to be a groundbreaking therapy in the field of nerve repair. Read More
